MRMI of EDB-FN was also used to successfully monitor the negative response of drug-resistant CRC tumors to the targeted pan-AKT inhibitor, MK2206-HCl 54, indicating the potential of EDB-FN as a therapy-predictive marker. Here, AKT1 is linked to colorectal carcinoma.